Quest Diagnostics Raises Full-Year Guidance on Strong Q2 Growth
Event summary
- Quest Diagnostics reported Q2 2026 revenues of $3.04 billion, up 10.2% YoY, with organic revenue growth across physician, hospital, and consumer channels.
- Adjusted diluted EPS grew by 19.1% YoY to $3.12 in Q2 2026.
- Full-year 2026 revenue guidance raised to between $11.95 billion and $12.05 billion, up from previous guidance of $11.78 billion to $11.90 billion.
- Company expanded automation solutions in lab operations and launched IntelliDraw™ to enhance specimen collection quality.
The big picture
Quest Diagnostics' strong Q2 performance reflects sustained demand for diagnostic insights across multiple channels. The company's focus on operational excellence through automation and strategic partnerships positions it well in the competitive healthcare diagnostics sector. The raised full-year guidance underscores confidence in continued growth, though maintaining this momentum will depend on executing its innovation strategy effectively.
What we're watching
- Sustainability of Growth
- Whether Quest Diagnostics can maintain its strong organic revenue growth and EPS expansion through the remainder of 2026.
- Operational Efficiency
- The pace at which automation solutions and IntelliDraw™ enhance productivity and service quality in lab operations.
- Strategic Partnerships
- How collaborations with Corewell Health, Fresenius Medical Care, and Flatiron Health will impact revenue growth and innovation.
Related topics